317 related articles for article (PubMed ID: 30971370)
21. Pulsed-dose-rate vs. high-dose-rate intracavitary radiotherapy for locally advanced carcinoma of cervix: A prospective randomized study.
Kumar P; Sharma DN; Kumar S; Gandhi AK; Rath GK; Julka PK
Brachytherapy; 2016; 15(3):327-332. PubMed ID: 26996595
[TBL] [Abstract][Full Text] [Related]
22. MRI-guided adaptive brachytherapy for locally advanced cervix cancer: Treatment outcomes from a single institution in Hong Kong.
Wu PY; Wong TPW; Yip YYC; Chang TYA; Chan LKL; Lee MCH; Law LYA; Yeung MWR; Soong SI
Brachytherapy; 2019; 18(2):171-179. PubMed ID: 30581053
[TBL] [Abstract][Full Text] [Related]
23. High-dose-rate vs. low-dose-rate interstitial brachytherapy boost for anal canal cancers.
Varela Cagetti L; Zemmour C; Salem N; Minsat M; Ferrè M; Mailleux H; Giovaninni M; Lelong B; De Chaisemartin C; Ries P; Poizat F; Tallet A; Moureau-Zabotto L
Brachytherapy; 2019; 18(6):814-822. PubMed ID: 31515067
[TBL] [Abstract][Full Text] [Related]
24. Low-Dose-Rate Brachytherapy Boosting Concurrent Chemoradiation as a Definitive Treatment Modality for Cervical Cancer: Long-term Clinical Results of Outcomes and Associated Toxicity.
Refaat T; Donnelly ED; Gentile M; Novak C; Yuan Y; Khedr GA; Helenowksi I; Lurain J; Schink J; Rademaker A; Sathiaseelan V; Strauss JB; Small W
Am J Clin Oncol; 2016 Apr; 39(2):196-203. PubMed ID: 24487420
[TBL] [Abstract][Full Text] [Related]
25. Results and complications of high dose rate and low dose rate brachytherapy in carcinoma of the cervix: Cerrahpaşa experience.
Okkan S; Atkovar G; Sahinler I; Oner Dinçbaş F; Koca A; Köksal S; Turkan S; Uzel R
Radiother Oncol; 2003 Apr; 67(1):97-105. PubMed ID: 12758245
[TBL] [Abstract][Full Text] [Related]
26. American Brachytherapy Task Group Report: A pooled analysis of clinical outcomes for high-dose-rate brachytherapy for cervical cancer.
Mayadev J; Viswanathan A; Liu Y; Li CS; Albuquerque K; Damato AL; Beriwal S; Erickson B
Brachytherapy; 2017; 16(1):22-43. PubMed ID: 28109631
[TBL] [Abstract][Full Text] [Related]
27. Clinical efficacy and toxicity of radio-chemotherapy and magnetic resonance imaging-guided brachytherapy for locally advanced cervical cancer patients: A mono-institutional experience.
Lakosi F; de Cuypere M; Viet Nguyen P; Jansen N; Warlimont B; Gulyban A; Gennigens C; Seidel L; Delbecque K; Coucke P; Hermesse J; Kridelka F
Acta Oncol; 2015; 54(9):1558-66. PubMed ID: 26406152
[TBL] [Abstract][Full Text] [Related]
28. Long-term outcomes of intensity-modulated radiation therapy (IMRT) and high dose rate brachytherapy as adjuvant therapy after radical hysterectomy for cervical cancer.
Contreras J; Srivastava A; Chundury A; Schwarz JK; Markovina S; Thaker PH; Massad LS; Mutch DG; Powell MA; Grigsby PW; Lin AJ
Int J Gynecol Cancer; 2020 Aug; 30(8):1157-1161. PubMed ID: 32527770
[TBL] [Abstract][Full Text] [Related]
29. Patterns of brachytherapy practice for patients with carcinoma of the cervix (1996-1999): a patterns of care study.
Erickson B; Eifel P; Moughan J; Rownd J; Iarocci T; Owen J
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1083-92. PubMed ID: 16099599
[TBL] [Abstract][Full Text] [Related]
30. High-dose-rate intracavitary brachytherapy (HDR-IC) in treatment of cervical carcinoma: 5-year results and implication of increased low-grade rectal complication on initiation of an HDR-IC fractionation scheme.
Wang CJ; Leung SW; Chen HC; Sun LM; Fang FM; Changchien CC; Huang EY; Wu JM; Chen CC
Int J Radiat Oncol Biol Phys; 1997 May; 38(2):391-8. PubMed ID: 9226328
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of nedaplatin-based concurrent chemoradiotherapy for FIGO Stage IB2-IVA cervical cancer and its clinical prognostic factors.
Fujiwara M; Isohashi F; Mabuchi S; Yoshioka Y; Seo Y; Suzuki O; Sumida I; Hayashi K; Kimura T; Ogawa K
J Radiat Res; 2015 Mar; 56(2):305-14. PubMed ID: 25428244
[TBL] [Abstract][Full Text] [Related]
32. Current controversies in high-dose-rate versus low-dose-rate brachytherapy for cervical cancer.
Stewart AJ; Viswanathan AN
Cancer; 2006 Sep; 107(5):908-15. PubMed ID: 16874815
[TBL] [Abstract][Full Text] [Related]
33. High-dose-rate vs. low-dose-rate intracavitary brachytherapy for carcinoma of the uterine cervix: Systematic review and meta-analysis.
Lee KK; Lee JY; Nam JM; Kim CB; Park KR
Brachytherapy; 2015; 14(4):449-57. PubMed ID: 25906951
[TBL] [Abstract][Full Text] [Related]
34. Brachytherapy for stage IIIB squamous cell carcinoma of the uterine cervix: survival and toxicity.
Zuliani AC; Cunha Mde O; Esteves SC; Teixeira JC
Rev Assoc Med Bras (1992); 2010; 56(1):37-40. PubMed ID: 20339784
[TBL] [Abstract][Full Text] [Related]
35. High-dose-rate brachytherapy monotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer.
Yamazaki H; Masui K; Suzuki G; Nakamura S; Yamada K; Okihara K; Shiraishi T; Yoshida K; Kotsuma T; Tanaka E; Otani K; Yoshioka Y; Ogawa K
Radiother Oncol; 2019 Mar; 132():162-170. PubMed ID: 30416045
[TBL] [Abstract][Full Text] [Related]
36. Helical tomotherapy with simultaneous integrated boost after laparoscopic staging in patients with cervical cancer: analysis of feasibility and early toxicity.
Marnitz S; Köhler C; Burova E; Wlodarczyk W; Jahn U; Grün A; Budach V; Stromberger C
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e137-43. PubMed ID: 21600704
[TBL] [Abstract][Full Text] [Related]
37. Twice-per-day fractionated high versus continuous low dose rate intracavitary therapy in the radical treatment of cervical cancer: a nonrandomized comparison of treatment results.
Hsu WL; Wu CJ; Jen YM; Yen SH; Lin KT; Ger LP; Kim RY
Int J Radiat Oncol Biol Phys; 1995 Jul; 32(5):1425-31. PubMed ID: 7635783
[TBL] [Abstract][Full Text] [Related]
38. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
Grills IS; Martinez AA; Hollander M; Huang R; Goldman K; Chen PY; Gustafson GS
J Urol; 2004 Mar; 171(3):1098-104. PubMed ID: 14767279
[TBL] [Abstract][Full Text] [Related]
39. Definitive radiotherapy based on HDR brachytherapy with iridium 192 in uterine cervix carcinoma: report on the Vienna University Hospital findings (1993-1997) compared to the preceding period in the context of ICRU 38 recommendations.
Pötter R; Knocke TH; Fellner C; Baldass M; Reinthaller A; Kucera H
Cancer Radiother; 2000; 4(2):159-72. PubMed ID: 10812362
[TBL] [Abstract][Full Text] [Related]
40. Low-Dose-Rate versus High-Dose-Rate intracavitary brachytherapy in cervical cancer - Final Results of a Phase III randomized trial.
Mahantshetty U; Lewis S; Engineer R; Swamidas J; Chopra S; Gurram L; Kinhikar R; Deshpande D; Kirisits C; Shrivastava S
Brachytherapy; 2021; 20(6):1146-1155. PubMed ID: 34598883
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
